The analyses of complement activation and CD4+, CD8+, or FoxP3+ T-cell infiltration in sections from 72 gliomas of WHO grade III and IV with or without IDH mutations showed significantly reduced complement activation and decreased numbers of tumor-infiltrating CD4+ and CD8+ T cells with comparable FoxP3+/CD4+ ratios. The gene discussed is IDH2; the disease is central nervous system cancer.